Fredun Pharmaceuticals Hits New 52-Week High of Rs. 1455 Amid Strong Momentum

Fredun Pharmaceuticals has reached a significant milestone by hitting a new 52-week high of Rs. 1455 today, October 6, 2025. This achievement marks a notable performance for the microcap company within the Pharmaceuticals & Biotechnology sector. The stock has shown impressive momentum, gaining 17.53% over the last nine consecutive days, and outperforming its sector by 2.98% today.
In terms of performance metrics, Fredun Pharmaceuticals has consistently traded above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. The company's one-year performance stands at an impressive 79.82%, significantly outpacing the Sensex, which has seen a decline of 0.56% over the same period.

Financially, Fredun Pharmaceuticals has demonstrated robust growth, with net sales increasing at an annual rate of 38.16% and operating profit rising by 56.18%. The company has reported positive results for the last five consecutive quarters, further solidifying its market position. With a return on capital employed (ROCE) of 16.8 and a PEG ratio of 0.8, Fredun Pharmaceuticals continues to showcase attractive valuation metrics in comparison to its peers.